Wellington Management, the top Bristol-Myers Squibb's shareholder, stated it would not support the US drugmaker's $74B worth takeover of the biotech firm Celgene.
Note: This section contains information in English only.
Thu, 28 Feb 2019 12:31:05 GMT
Source: Dukascopy Bank SA